Clinical Trials Logo

Clinical Trial Summary

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled. The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.


Clinical Trial Description

Study PGG-BCA-2121 is a multicenter, open-label, Phase 2 study of patients with metastatic breast cancer who have progressed through prior hormonal therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. All patients will be immune checkpoint inhibitor-naive. A total of 47 mBCA patients will be enrolled to treatment with the combination of Imprime PGG 4 mg/kg with pembrolizumab 200mg. Patients will be screened and enrolled if baseline ABA level is greater than or equal to 20 mcg/mL (ABA+) and if all other inclusion/ exclusion criteria are met (ABA is measured in peripheral blood). Approximately 200 patients will be screened (allows for pre/ early screening for ABA levels). Dosing will occur in three-week cycles. On Day 1 of each cycle, all patients will receive Imprime PGG 4 mg/kg IV over ~ 2-4 hr (based on body weight) followed by pembrolizumab 200 mg, IV over 30 min. On Day 8 and 15 of each cycle, patients will receive only Imprime PGG. Premedications (defined by the protocol) will be administered ~30 min before initiation of Imprime PGG during Cycles 1-3 (thereafter at the physician's discretion). Patients will dose to confirmed progression, safety event, or other administrative reason requiring discontinuation; all patients are allowed to dose up to 35 cycles. For all patients, a baseline CT/MRI will be conducted. The first scan to assess response will be conducted 12 wks post-initiation of study treatment (pre-Cycle 5) and then q12wks thereafter until confirmed progression or discontinuation. At any time, if a patient's response is progressive disease (PD), the patient will dose for an additional 4-8 wks (physician discretion) followed by a confirmatory scan. If that scan shows progressive disease, the patient will move into overall survival monitoring. Response will be assessed by RECISTv1.1 and iRECIST will be applied by the Investigator solely for clinical management of patients as described below. All scans will be read locally and by blinded central review. At screening, an official historical diagnostic pathology report +/- archival tissue (formalin-fixed paraffin embedded [FFPE]) will be retrieved to confirm historical diagnosis of ER/PR status. All patients will have a newly obtained core or excisional biopsy at 6 wks after initiation of study treatment. Fresh biopsies at baseline and progression or End of Treatment are strongly encouraged but not mandated. Preferably, biopsies should be non-bone and if amenable, a biopsy of a liver lesion not designated as target or non-target is preferred. Patients with bone only metastases (BOM) are not eligible, except if such lesions have a distinct, associated soft tissue component that is measurable as per RECIST 1.1. Blood samples for safety monitoring and translational endpoints will be collected on all patients as detailed in the Schedule of Activities. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05159778
Study type Interventional
Source HiberCell, Inc.
Contact
Status Completed
Phase Phase 2
Start date November 9, 2021
Completion date April 12, 2023

See also
  Status Clinical Trial Phase
Completed NCT02378337 - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality N/A
Completed NCT01953003 - Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase 3
Not yet recruiting NCT01395706 - ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes Phase 2
Enrolling by invitation NCT05486520 - Low-field MRI for Breast Cancer Screening N/A
Active, not recruiting NCT03379428 - Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Withdrawn NCT03261323 - Breast Reconstruction Following Breast Cancer in Very High Risk Patients N/A
Recruiting NCT04669873 - Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery N/A
Completed NCT02408393 - MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery Phase 3
Completed NCT03289819 - Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC Phase 2
Completed NCT02495363 - Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
Completed NCT03159195 - Ibrance Real World Insights
Completed NCT03425656 - Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer Phase 3
Active, not recruiting NCT05033756 - Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO Phase 2
Not yet recruiting NCT01641003 - Isolation and Characterization of Cancer Stem Cells Using iFP Technique N/A
Active, not recruiting NCT05364450 - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors N/A
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Active, not recruiting NCT02204098 - Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Phase 1
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1
Active, not recruiting NCT02187991 - Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Phase 2